Colorectal cancer test is FDA moment of sorts

Share this article:

Exact Sciences hit a two-fer with Monday's approval of its colorectal cancer test: Cologuard was the first approved fecal-based screening test for the disease, and it was also the first product the FDA and the Centers for Medicare and Medicaid Services approved on the very same day through the Parallel Review program.

Regulatory Focus explains that the idea for the Parallel Review program started in 2011 and that it has had some setbacks, such as in January, when the two government agencies were set to approve Medtronic's Symplicity Renal Denervation Device, but it failed to hit its Phase-III clinical trial goals and could not be greenlighted.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.